Skip to main content

Table 2 The baseline characteristics in T2DM patients with various MTNR1B rs10830963 genotypes before treatment with nateglinide (n = 200)

From: Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Parameters

MTNR1B rs10830963 genotype

P value

CC

CG

GG

N (men/women)

70(40/30)

90(48/42)

40(23/17)

0.850Δ

Age (years)

47.81 ± 10.82

48.01 ± 12.04

47.09 ± 13.92

0.921

BMI (kg/m2)

26.41 ± 3.24

25.43 ± 3.31

26.59 ± 4.11

0.104

WHR

0.92 ± 0.06

0.91 ± 0.06

0.92 ± 0.08

0.552#

FPG (mmol/L)

9.61 ± 2.01

9.91 ± 2.79

10.82 ± 1.79

0.034*

PPG (mmol/L)

15.36 ± 2.46

14.21 ± 4.39

14.69 ± 5.71

0.224

FINS (mU/L)

8.56 ± 5.39

7.37 ± 6.99

7.53 ± 6.39

0.477#

PINS (mU/L)

30.01 ± 17.10

28.11 ± 20.51

33.51 ± 17.49

0.320

HOMA-IR

3.27 ± 1.30

3.09 ± 3.21

4.01 ± 2.47

0.160

HbA1c (%)

9.71 ± 1.97

9.11 ± 2.62

9.95 ± 2.04

0.098

TG (mmol/L)

2.25 ± 1.38

2.31 ± 2.13

1.97 ± 1.52

0.596

TC (mmol/L)

5.21 ± 1.29

4.99 ± 1.31

5.49 ± 1.51

0.143

HDL-c (mmol/L)

1.28 ± 0.95

1.33 ± 0.59

1.41 ± 0.29

0.645

LDL-c (mmol/L)

3.45 ± 0.68

3.61 ± 1.19

3.80 ± 0.93

0.199#

  1. BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol
  2. Data are given as (mean ± SD). P values represent statistical differences among the three different genotypes by the one-way ANOVA. ΔP values are determined by the Pearson chi-square test. #P values are determined by the Kruskal–Wallis test. *P < 0.05
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us